There are currently 4 clinical trials in Huntsville, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including . Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: North Houston Cancer Clinics - Huntsville, Huntsville, Texas
Conditions: Myelodysplastic Syndromes
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
Recruiting
This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Huntsville Research Institute LLC, Huntsville, Texas
Conditions: OSA
Study to Assess SLN124 in Patients With Polycythemia Vera
Recruiting
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: North Houston Cancer Clinics, Huntsville, Texas
Conditions: Polycythemia Vera
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
Recruiting
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: North Houston Cancer Clinics, Huntsville, Texas
Conditions: Advanced Solid Malignant Tumor, Small Cell Lung Cancer